<DOC>
	<DOCNO>NCT02692599</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity safety live attenuate mumps vaccine healthy infant 8 - 18 month old commercialized live attenuate mumps vaccine control vaccine .</brief_summary>
	<brief_title>Safety Immunogenicity Study Live Attenuated Mumps Vaccines Healthy Infants</brief_title>
	<detailed_description>This study randomize , blind , single-center , control phase III clinical trial . The purpose study evaluate immunogenicity safety live attenuate mumps vaccine manufacture Sinovac ( Dalian ) Vaccine Technology Co. , Ltd . The control vaccine commercialize live attenuate mumps vaccine manufacture Zhejiang VACN bio-pharmaceutical Co. Ltd. All participant healthy infant 8 - 18 month old , randomly assign experimental group control group ratio 1:1 .</detailed_description>
	<mesh_term>Mumps</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy volunteer 8 18 month old ; Proven legal identity ; Guardian ( ) volunteer capable understanding write consent form , form sign infant include study ; Complying requirement study protocol ; Axillaty temperature &gt; 37.0 Â°C ; Any significant abnormity heart , lung , liver , spleen , lymph node , pharynx ; Acute disease acute stage chronic disease within 7 day prior study entry ; Prior vaccination mumps vaccine history mumps infection ; History allergy vaccine vaccine ingredient , serious adverse reaction ( ) vaccination , urticaria , difficulty breathing , angioneurotic edema , abdominal pain , etc ; Receipt follow product : 1 . Any subunit vaccine inactivate vaccine within 14 day prior study entry ; 2 . Any live attenuate vaccine within 28 day prior study entry ; 3 . Any investigational medicine ( ) within 30 day prior study entry ; 4 . Blood product ( e.g. , immunoglobulin ) within 3 month prior study entry ; 5 . Any immunosuppressant , cytotoxic medicine , inhaled corticosteroid ( except corticosteroid spray treatment allergic rhinitis corticosteroid treatment surface acute noncomplicated dermatitis ) within 6 month prior study entry ; Epilepsy ( except febrile seizure ) , history seizure convulsion , family history mental illness ; Autoimmune disease immunodeficiency ; Congenital malformation , developmental disorder , serious chronic disease ( Down 's syndrome , diabetes , sickle cell anemia neurological disorder ; Severe malnutrition ; Diagnosed coagulation function abnormal ( e.g. , coagulation factor deficiency , coagulation disorder , platelet abnormality ) ; Any factor suggest volunteer unsuitable study base opinion investigator ; Participants follow condition day 0 28 study would include full analysis set ( FAS ) , would exclude per protocol set ( PPS ) : 1 . Receipt investigational unregistered product ( drug vaccine ) ; 2 . Receipt immunosuppressant ( corticosteroid dosage equivalent 0.5 mg prednisone/kg weight/day ) &gt; 14 day consecutively , except inhalant locally administrate corticosteroid ; 3 . Receipt immunoglobulin and/or blood product ; 4 . Newly diagnose autoimmune disease immunodeficiency ( e.g. , HIV infection ) ;</criteria>
	<gender>All</gender>
	<minimum_age>8 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>live attenuate mumps vaccine</keyword>
	<keyword>safety</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>infant</keyword>
</DOC>